Patent · US Active

Hepatitis C virus inhibitors

US9770439B2 · kind B2 · utility

0Cited by

18References

7Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Piyasena Hewawasam · Middletown, US
Omar D. Lopez · Wallingford, US
Yong Tu · Cheshire, US
Alan Xiangdong Wang · Guilford, US
Ningning Xu · Lawrenceville, US
John F. Kadow · Wallingford, US
Nicholas A. Meanwell · East Hampton, US
Samayamunthula Venkata Satya Arun Kumar Gupta · Bengaluru, IN
Indasi J. Gopi Kumar · Bengaluru, IN
Suresh Kumar Ponugupati · Bengaluru, IN
Makonen Belema · North Haven, US

Key dates

Filing date	Jun 29, 2015
Grant date	Sep 26, 2017
Priority date	—
Expiry date	Jun 29, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D493/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.